"シオノギ製薬" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonShionogi & Co., Ltd.'s (TSE:4507) Stock Is Going Strong: Is the Market Following Fundamentals? - ...
Shionogi & Co., Ltd.'s (TSE:4507) Stock Is Going Strong: Is the Market Following Fundamentals? simplywall.st
Shionogi to Announce Personnel Reassignment｜ 塩野義製薬 - Shionogi Inc.
Shionogi to Announce Personnel Reassignment｜ 塩野義製薬 Shionogi Inc.
Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments - BioSpec...
Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments BioSpectrum Asia
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults Fierce Biotech
Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology
Shionogi awarded $375m from HHS for preventative Covid-19 injectable Pharmaceutical Technology
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - GlobeNewswire
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia GlobeNewswire
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial Clinical Trials Arena
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance - ContagionLive
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance ContagionLive
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Reuters
Shionogi's RSV antiviral succeeds in mid-stage study - FirstWord Pharma
Shionogi's RSV antiviral succeeds in mid-stage study FirstWord Pharma
Shionogi gets approval in Japan for ADHD digital therapeutic - pharmaphorum
Shionogi gets approval in Japan for ADHD digital therapeutic pharmaphorum
Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants - BioWorld MedTech
Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants BioWorld MedTech
David Benadon｜ 塩野義製薬 - Shionogi Inc.
David Benadon｜ 塩野義製薬 Shionogi Inc.
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...
Institutional owners may take dramatic actions as Shionogi & Co., Ltd.'s (TSE:4507) recent 7.5% d...
Institutional owners may take dramatic actions as Shionogi & Co., Ltd.'s (TSE:4507) recent 7.5% drop adds to one-year losses simplywall.st
Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.
Notice of Head Office Relocation｜ 塩野義製薬 Shionogi Inc.
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19...
Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library ...
Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library | Shionogi & Co., Ltd. Shionogi Inc.
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study FirstWord Pharma
Shionogi to acquire full ownership of joint ventures with Ping An - The Pharma Letter
Shionogi to acquire full ownership of joint ventures with Ping An The Pharma Letter
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi Inc.
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 Shionogi Inc.
Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan The Pharma Letter
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
TABLE-Shionogi -2024/25 div forecast - TradingView
TABLE-Shionogi -2024/25 div forecast TradingView
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - Eura...
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO Euractiv
Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter
Shionogi’s ensitrelvir prevents symptomatic COVID-19 The Pharma Letter
A Pill to Prevent COVID-19 Shows Promise - Time Magazine
A Pill to Prevent COVID-19 Shows Promise Time Magazine
Shionogi files NDA in Japan for zuranolone in MDD - The Pharma Letter
Shionogi files NDA in Japan for zuranolone in MDD The Pharma Letter
Apnimed Provides Clinical Updates for Multiple Product Candidates - PR Newswire
Apnimed Provides Clinical Updates for Multiple Product Candidates PR Newswire
Antibiotics, an important but tricky business, says Shionogi CEO - Euractiv
Antibiotics, an important but tricky business, says Shionogi CEO Euractiv
BARDA to fund development of COVID preventive drug - CIDRAP
Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infection...
Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infections: GlobalData Express Pharma
Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 - Endpoints News
Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 Endpoints News
Shionogi presents largest global real-world evidence study of cefiderocol - The Pharma Letter
Shionogi presents largest global real-world evidence study of cefiderocol The Pharma Letter
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment Precedence Research
Shionogi’s Ensitrelvir Shows Promise in COVID-19 Prevention - TipRanks
Shionogi’s Ensitrelvir Shows Promise in COVID-19 Prevention TipRanks
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand BioSpectrum Asia
The Leadership Connection - BOSS Magazine
The Leadership Connection BOSS Magazine
Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city re...
Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city resilient to infectious diseases BioSpectrum Asia
Shionogi - Technology Magazine
Shionogi Technology Magazine
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yicai
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi Yicai
Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment - The Hear...
Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment The Hearing Review
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - biocentury.com
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout biocentury.com
Shionogi's RSV antiviral shows promise in hVIVO trial - Investing.com
Shionogi's RSV antiviral shows promise in hVIVO trial Investing.com
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld MedTech
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models BioWorld MedTech
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego - Genetic Engineering and Biotechnology...
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego Genetic Engineering and Biotechnology News
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin...
APAC Healthcare Weekly (April 6)- Nippon Shinyaku, Shionogi, Beigene, Celltrion, Mesoblast, Lupin Smartkarma
APAC Healthcare Weekly (Mar 30)- Eisai, Kaken, Mochida, Shionogi, SK Bioscience, PharmaEssentia -...
APAC Healthcare Weekly (Mar 30)- Eisai, Kaken, Mochida, Shionogi, SK Bioscience, PharmaEssentia Smartkarma
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results - Share Talk
hVIVO PLC (AIM:HVO) Shionogi reports positive RSV trial results Share Talk
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters
hVIVO's human challenge trial shows strong results for Shionogi's RSV antiviral - Proactive Inves...
hVIVO's human challenge trial shows strong results for Shionogi's RSV antiviral Proactive Investors
Shionogi's antiviral comes up short in global COVID-19 trial - Fierce Pharma
Shionogi's antiviral comes up short in global COVID-19 trial Fierce Pharma
Shionogi secures license for Maze’s Pompe disease treatment - Pharmaceutical Technology
Shionogi secures license for Maze’s Pompe disease treatment Pharmaceutical Technology
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M Fierce Biotech
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...
Masahiro Fujita - Shionogi Inc.
Masahiro Fujita Shionogi Inc.
“Pharmaceutical Education” by Virtual Employee - Shionogi Inc.
“Pharmaceutical Education” by Virtual Employee Shionogi Inc.
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health (NIH) (.gov)
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld MedTech
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld MedTech
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BioSpectrum ...
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss BioSpectrum Asia
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for...
Maze lands new partner for Pompe drug, after Sanofi pact came apart - BioPharma Dive
Maze lands new partner for Pompe drug, after Sanofi pact came apart BioPharma Dive
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug - sta...
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug statnews.com
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value Shionogi Inc.
Shimadzu, Shionogi unveil international wastewater-based epidemiology lab at University of Tokyo,...
Shimadzu, Shionogi unveil international wastewater-based epidemiology lab at University of Tokyo, Japan BioSpectrum Asia
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacteri...
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative
Zuranolone to face challenges in Japan’s MDD market despite demonstrating rapid onset of action: ...
Zuranolone to face challenges in Japan’s MDD market despite demonstrating rapid onset of action: GlobalData Express Pharma
Margaret Borys - Shionogi Inc.
Margaret Borys Shionogi Inc.
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
Message from Top Management - Shionogi Inc.
Message from Top Management Shionogi Inc.
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval - Reuters
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval Reuters
What we stand for: Takeki Uehara - Shionogi Inc.
What we stand for: Takeki Uehara Shionogi Inc.
Japan's Shionogi seeks approval for COVID-19 pill - Reuters
F2G and Shionogi Present Full Data Set from Pivotal Phase - GlobeNewswire
F2G and Shionogi Present Full Data Set from Pivotal Phase GlobeNewswire
Nathan McCutcheon - Shionogi Inc.
Nathan McCutcheon Shionogi Inc.
Shionogi gains rights to Maze’s investigational Pompe disease therapy for $150m upfront - PMLiVE
Shionogi gains rights to Maze’s investigational Pompe disease therapy for $150m upfront PMLiVE
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move The Business Journals
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus Reuters
FDA declines to approve Shionogi, F2G's antifungal olorofim - FirstWord Pharma
FDA declines to approve Shionogi, F2G's antifungal olorofim FirstWord Pharma
Chris Klein - Shionogi Inc.
Chris Klein Shionogi Inc.
Shionogi reports data from Phase III portion of Covid-19 drug trial - Clinical Trials Arena
Shionogi reports data from Phase III portion of Covid-19 drug trial Clinical Trials Arena
Tadashi Hara - Shionogi Inc.
Tadashi Hara Shionogi Inc.
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Hea...
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam Business Wire
GSK to develop longer-acting therapy for HIV with Japan's Shionogi - Reuters
GSK to develop longer-acting therapy for HIV with Japan's Shionogi Reuters
AWS Case Study: Shionogi & Co., Ltd. - Amazon Web Services (AWS)
AWS Case Study: Shionogi & Co., Ltd. Amazon Web Services (AWS)
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval - Reuters
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval Reuters
History - Shionogi Inc.
History Shionogi Inc.
Notice Regarding the Launch of the new SHIONOGI Group Brand - Shionogi Inc.
Notice Regarding the Launch of the new SHIONOGI Group Brand Shionogi Inc.
Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial...
After scuppered Sanofi deal, Maze navigates its way to new partner for Pompe drug - FirstWord Pharma
After scuppered Sanofi deal, Maze navigates its way to new partner for Pompe drug FirstWord Pharma
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agen...
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S‑217622 Business Wire